{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T23:51:49.626247+00:00","company":{"ticker":"OPK","cik":944809,"company_name":"OPKO HEALTH, INC."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"f65e36055d5278ccfee8cdaad352cf564d14df38","cik":944809,"ticker":"OPK","company_name":"OPKO HEALTH, INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":"$0.07 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$54.8 million","period_text":"the three months ended March 31, 2026","report_date":"2026-04-28","result_type":"reported_results","revenue_text":"$124.2 million"},"claim":"OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.","evidence_excerpt":"each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-186939","anchor_url":"https://secwatch.observer/filing/0001193125-26-186939#claim-f65e36055d5278ccfee8cdaad352cf564d14df38","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm"},{"fact_type":"earnings_release","fact_key":"7396bb910e58437418ac9f351c8f9fd2ca429bb2","cik":944809,"ticker":"OPK","company_name":"OPKO HEALTH, INC.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.12 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$81.8 million, or $0.12 per share","period_text":"three months ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$173.7 million"},"claim":"OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.","evidence_excerpt":"was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-015074","anchor_url":"https://secwatch.observer/filing/0001437749-24-015074#claim-7396bb910e58437418ac9f351c8f9fd2ca429bb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm"}]}